PCVX:NSD-Vaxcyte Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 77.79

Change

+1.53 (+2.01)%

Market Cap

USD 8.22B

Volume

0.37M

Analyst Target

USD 49.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-05 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+1.76 (+0.39%)

USD 119.56B
REGN Regeneron Pharmaceuticals Inc

-1.77 (-0.17%)

USD 114.65B
ALNY Alnylam Pharmaceuticals Inc

-1.54 (-0.57%)

USD 34.86B
ARGX argenx NV ADR

-13.04 (-2.40%)

USD 32.89B
MRNA Moderna Inc

-0.87 (-1.42%)

USD 25.27B
BGNE BeiGene Ltd

+12.40 (+5.31%)

USD 24.38B
RPRX Royalty Pharma Plc

N/A

USD 16.72B
UTHR United Therapeutics Corporatio..

+5.86 (+1.67%)

USD 15.95B
SMMT Summit Therapeutics PLC

+0.48 (+2.58%)

USD 15.35B
BMRN Biomarin Pharmaceutical Inc

+1.35 (+1.98%)

USD 13.44B

ETFs Containing PCVX

HVAX:CA 4.86 % 0.00 %

N/A

N/A
MMSC First Trust Multi-Manager.. 1.31 % 0.00 %

+0.28 (+1.45%)

USD 0.02B
VTWG Vanguard Russell 2000 Gro.. 0.65 % 0.20 %

+3.48 (+1.45%)

USD 1.02B
UWM ProShares Ultra Russell20.. 0.41 % 0.95 %

+1.13 (+1.45%)

USD 0.29B
R2US:SW SPDR® Russell 2000 US Sm.. 0.34 % 0.00 %

+0.93 (+1.45%)

USD 3.30B
XRS2:SW Xtrackers Russell 2000 UC.. 0.33 % 0.00 %

+5.60 (+1.45%)

USD 1.38B
RSSL Global X Funds 0.33 % 0.00 %

+1.23 (+1.45%)

N/A
VTWO Vanguard Russell 2000 Ind.. 0.33 % 0.15 %

+1.23 (+1.45%)

USD 11.71B
BBC Virtus LifeSci Biotech Cl.. 0.00 % 0.79 %

+0.49 (+1.45%)

USD 0.01B
HDG ProShares Hedge Replicati.. 0.00 % 0.95 %

+0.20 (+1.45%)

USD 0.03B
IWM iShares Russell 2000 ETF 0.00 % 0.19 %

+3.02 (+1.45%)

N/A
IWO iShares Russell 2000 Grow.. 0.00 % 0.24 %

+4.68 (+1.45%)

N/A
BTEC 0.00 % 0.42 %

N/A

N/A
VRTGX Vanguard Russell 2000 Gro.. 0.00 % 0.00 %

N/A

USD 1.19B
VRTIX Vanguard Russell 2000 Ind.. 0.00 % 0.00 %

+5.01 (+1.45%)

USD 10.02B
SCHA Schwab U.S. Small-Cap ETF 0.00 % 0.05 %

+0.66 (+1.45%)

USD 17.80B
URTY ProShares UltraPro Russel.. 0.00 % 0.95 %

+2.09 (+1.45%)

USD 0.46B
R2SC:LSE SPDR® Russell 2000 US Sm.. 0.00 % 0.00 %

+0.45 (+1.45%)

USD 3.31B
R2US:LSE SPDR® Russell 2000 US Sm.. 0.00 % 0.00 %

+0.52 (+1.45%)

USD 3.31B
XRSG:LSE Xtrackers Russell 2000 UC.. 0.00 % 0.00 %

+212.50 (+1.45%)

USD 1.38B
XRSU:LSE Xtrackers Russell 2000 UC.. 0.00 % 0.00 %

+2.48 (+1.45%)

USD 1.38B
R2US:PA SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

+0.77 (+1.45%)

USD 3.34B
XRS2:F Xtrackers (IE) Public Lim.. 0.00 % 0.00 %

N/A

USD 1.19B
ZPRR:F SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

N/A

USD 2.91B
XRS2:XETRA Xtrackers Russell 2000 UC.. 0.00 % 0.00 %

+3.60 (+1.45%)

USD 1.19B
ZPRR:XETRA SPDR® Russell 2000 US Sm.. 0.00 % 0.00 %

+0.78 (+1.45%)

USD 2.91B
GERM 0.00 % 0.00 %

N/A

N/A
ISCG iShares Morningstar Small.. 0.00 % 0.00 %

+0.65 (+1.45%)

USD 0.61B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 23.87% 79% B- 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.87% 79% B- 85% B
Trailing 12 Months  
Capital Gain 67.04% 89% A- 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 67.04% 89% A- 93% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 28.55% 78% C+ 84% B
Dividend Return 28.55% 78% C+ 84% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 51.24% 55% F 33% F
Risk Adjusted Return 55.72% 96% N/A 83% B
Market Capitalization 8.22B 98% N/A 92% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector